OpenOnco · Treatment Plan

Treatment plan — Salivary gland carcinoma

PLAN-COVERAGE-SALIVARY-001-V1 · v1 · 2026-06-27

Patient

COVERAGE-SALIVARY-001 · Algorithm: ALGO-SALIVARY-1L

DiagnosisSalivary gland carcinoma

MOH / ICD-10C07, C08

ICD-O-38500/3; C07, C08

Clinical significance of mutations (ESCAT)

Tumor-board context — the engine does not use these tiers to rank tracks

Biomarker	Variant	ESCAT	Evidence	Clinical significance	Drugs	Sources
No clinically actionable variants matched in this profile.

Primary current-line option

Standard plan

★ DEFAULT

Indication

IND-SALIVARY-PALLIATIVE-PACLITAXEL-CARBO

Regimen

Paclitaxel + carboplatin (salivary gland carcinoma, palliative)

Drugs + NSZU

Paclitaxel (DRUG-PACLITAXEL) Paclitaxel 175 mg/m² · Per regimen schedule · IV ✓ NSZU covered
Carboplatin (DRUG-CARBOPLATIN) carboplatin AUC 5 IV q3w × 6 cycles · Per regimen schedule · IV ⚠ NSZU — not for this indication

Reason

Primary current-line option selected by ALGO-SALIVARY-1L at the fallback path.

Timeline

Treatment timeline — derived from regimen + monitoring schedule

Standard plan

Induction · Paclitaxel + carboplatin (salivary gland carcinoma, palliative)

21-day cycles × 6 cycles or until progression / toxicity

MDT brief

Data quality

Usable with caveats. No critical default-track gap was found, but the MDT should review the listed caveats before final sign-off.

Biomarker coverage: 0/0 known (100%), 0 missing, 0 default-track gaps
Unevaluated RedFlags: RF-SALIVARY-ADVANCED-PALLIATIVE, RF-SALIVARY-FRAILTY-AGE, RF-SALIVARY-HIGH-RISK-BIOLOGY, RF-SALIVARY-INFECTION-SCREENING, RF-SALIVARY-ORGAN-DYSFUNCTION, RF-SALIVARY-TRANSFORMATION-PROGRESSION

Technical MDT skill metadata (0/16 activated in this plan)

All registered virtual specialists. ✓ — activated for this case; ○ — not activated (available for other clinical scenarios).

Specialist	skill_id	Version	Last reviewed	Domain
Cellular therapy specialist (CAR-T)	`cellular_therapy_specialist`	v0.1.0	2026-04-25	cellular_therapy
Clinical pharmacist	`clinical_pharmacist`	v0.1.0	2026-04-25	clinical_pharmacy
Hematologist / oncohematologist	`hematologist`	v0.1.0	2026-04-25	hematology_oncology
Hematopathologist (lymphoma / leukemia / myeloma)	`hematopathologist`	v0.1.0	2026-04-25	hematopathology
Infectious disease / hepatology	`infectious_disease_hepatology`	v0.1.0	2026-04-25	infectious_diseases
Medical oncologist (solid-tumor chemotherapist)	`medical_oncologist`	v0.1.0	2026-04-25	solid_oncology
Molecular geneticist / molecular oncologist	`molecular_geneticist`	v0.1.0	2026-04-25	molecular_oncology
Palliative care	`palliative_care`	v0.1.0	2026-04-25	palliative_care
Pathologist (general)	`pathologist`	v0.1.0	2026-04-25	pathology
Primary care / family physician	`primary_care`	v0.1.0	2026-04-25	primary_care
Psycho-oncologist	`psychologist`	v0.1.0	2026-04-25	psychosocial
Radiation oncologist	`radiation_oncologist`	v0.1.0	2026-04-25	radiation_oncology
Radiologist	`radiologist`	v0.1.0	2026-04-25	diagnostic_imaging
Social worker / case manager	`social_worker_case_manager`	v0.1.0	2026-04-25	psychosocial
Surgical oncologist	`surgical_oncologist`	v0.1.0	2026-04-25	surgical_oncology
Transplant specialist (BMT)	`transplant_specialist`	v0.1.0	2026-04-25	cellular_therapy

Sources cited

SRC-NCCN-THYROID-2025: NCCN Clinical Practice Guidelines — Thyroid Carcinoma (2025.v2)

Experimental options (clinical trials)

Third plan track — open-enrollment trials from ClinicalTrials.gov. Render-time metadata; engine selection is not affected by this block (CHARTER §8.3). Last synced: 2026-06-27.

NCT	Title	Phase	Status	Sponsor	UA	Signals
NCT07118176	Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers	PHASE1	RECRUITING	Jonsson Comprehensive Cancer Center	—	Phase 1 only Small N (<50) Single country
NCT07507578	A Multi-omics Approach to Disclose Progression and Underlying Biology of Head and Neck Adenoid Cystic Carcinoma	N/A	RECRUITING	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	—	Single country
NCT06393140	The Study on the Mechanism of Radiotherapy-elicited Immune Response	N/A	RECRUITING	Fudan University	—	Single country
NCT07124000	DESTINY-PANTUMOUR04	N/A	RECRUITING	AstraZeneca	—	Surrogate endpoint only Single country
NCT05727410	Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland Carcinoma	PHASE2	RECRUITING	Myung-Ju Ahn	—	Surrogate endpoint only Single country
NCT04214366	Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation	PHASE2	RECRUITING	Heidelberg University	—	Single country
NCT06805617	A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers	PHASE2	RECRUITING	Glenn J. Hanna	—	Small N (<50) Surrogate endpoint only Single country
NCT05483374	The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers	N/A	RECRUITING	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	—	—
NCT06923826	Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)	PHASE2	RECRUITING	National University Hospital, Singapore	—	Small N (<50) Surrogate endpoint only Single country
NCT06356272	Oropharynx (OPX) Biomarker Trial	N/A	RECRUITING	Mayo Clinic	—	Single country

Verify recruitment status directly with the trial site. ctgov data can lag behind current UA-site status.

Option availability in Ukraine

Per-track UA registration · NSZU · cost · access pathway. Render-time metadata; engine selection does not depend on these fields (CHARTER §8.3).

Option	UA registration	NSZU	Cost orientation	Access pathway
Standard plan Paclitaxel + carboplatin (salivary gland carcinoma, palliative) (REG-PACLITAXEL-CARBOPLATIN-SALIVARY)	✓ registered	✓ covered	₴-? — verify pathway	NSZU formulary
Trial · NCT07118176 Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT07507578 A Multi-omics Approach to Disclose Progression and Underlying Biology of Head and Neck Adenoid Cystic Carcinoma No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06393140 The Study on the Mechanism of Radiotherapy-elicited Immune Response No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT07124000 DESTINY-PANTUMOUR04 No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT05727410 Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland Carcinoma No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT04214366 Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06805617 A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT05483374 The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06923826 Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC) No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06356272 Oropharynx (OPX) Biomarker Trial No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor

Cost information is orientation. Verify with a specific pharmacy / foundation / trial site. Status updated: 2026-06-27.

plan_id: PLAN-COVERAGE-SALIVARY-001-V1 | version: 1 | generated: 2026-06-27T09:41:00.700690+00:00

Per FDA non-device CDS positioning (CHARTER §15): Outpatient oncology treatment planning to support tumor-board discussion. Not a medical device; not for autonomous clinical decision-making.

Per FDA non-device CDS positioning (CHARTER §15): Both treatment options below are presented for review. The engine's selection of a 'recommended' default does not constitute a clinical decision. Final treatment selection requires HCP judgment incorporating information not available to the system.

This document is an informational resource supporting tumor-board discussion (per CHARTER §11). It is not a system that makes clinical decisions. Every recommendation must be verified by the treating physician.